

SHINGLES CAN STRIKE AT ANY TIME^{1,2} WHEN YOUR PATIENTS' SLEEVES ARE UP, SPEAK UP ABOUT COADMINISTRATION



GUIDANCE FROM THE CDC

According to the CDC, recombinant and adjuvanted vaccines (like SHINGRIX) can be administered concomitantly at different anatomic sites with other adult vaccines. This includes COVID-19 vaccines.³



Scan QR code or visit the
CDC SHINGRIX recommendation page
to review guidance

The Prescribing Information for SHINGRIX includes data on coadministration of SHINGRIX with certain flu, pneumococcal, and Tdap vaccines. Data are limited on concomitant administration with other vaccines.⁴

Results from open-label studies in adults ≥50 years old who received SHINGRIX concomitantly administered with another vaccine^{4,*}

FLUARIX QUADRIVALENT (Influenza Vaccine)[†] coadministered with SHINGRIX; **no evidence of interference in the immune response** to any of the antigens contained in SHINGRIX or FLUARIX QUADRIVALENT was demonstrated.

PREVNAR 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM₁₉₇ Protein]) coadministered with SHINGRIX; **no evidence of interference in the immune response** to the antigens contained in SHINGRIX or PREVNAR 13 was demonstrated when the vaccines were administered concomitantly.

BOOSTRIX (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed) coadministered with SHINGRIX; **no evidence of interference in the immune response to the antigen in SHINGRIX or the antigens in BOOSTRIX was demonstrated, with the exception of one of the pertussis antigens (pertactin).**

The clinical significance of the reduced immune response to pertactin is unknown.

PNEUMOVAX 23 (Pneumococcal Vaccine Polyvalent) coadministered with SHINGRIX; **no evidence of interference in the immune response** to the antigen contained in SHINGRIX or to the 12 evaluated antigens contained in PNEUMOVAX 23 was demonstrated.

When the first dose of SHINGRIX was coadministered with PNEUMOVAX 23 compared to when SHINGRIX was given alone, **a greater percentage of subjects reported fever (16% vs 7%, respectively) and shivering (21% vs 7%, respectively)** within the 7-day postvaccination period.

*For study designs and dosing, please see full Prescribing Information for SHINGRIX.

†Data for FLUARIX QUADRIVALENT are relevant to FLUARIX (Influenza Vaccine) because both vaccines are manufactured using the same process and have overlapping compositions.

Indication

SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

Important Safety Information

- SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
- Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX

Please see additional Important Safety Information on the second page and full Prescribing Information also available at SHINGRIXHCP.com.

MAKE A STRONG RECOMMENDATION FOR SHINGRIX TODAY

WHAT YOU SAY MATTERS

Protecting patients starts with a strong recommendation from you

To communicate the importance of vaccination with SHINGRIX, follow a simple 3-step plan:

- 1 EDUCATE PATIENTS ABOUT SHINGLES**
- 2 MAKE THE RISK OF SHINGLES RELATABLE**
- 3 ADMINISTER OR SCHEDULE SHINGRIX TODAY**



Scan QR code or visit SHINGRIXHCP.com to view the [What to Expect pamphlet](#) for patients

Now is the time to consider coadministration of SHINGRIX with other adult vaccines, or encourage your patients to book an appointment at ScheduleSHINGRIX.com

Important Safety Information (cont'd)

- In a postmarketing observational study, an increased risk of Guillain-Barré syndrome was observed during the 42 days following vaccination with SHINGRIX
- Syncope (fainting) can be associated with the administration of injectable vaccines, including SHINGRIX. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
- Solicited local adverse reactions reported in individuals aged 50 years and older were pain (78%), redness (38%), and swelling (26%)
- Solicited general adverse reactions reported in individuals aged 50 years and older were myalgia (45%), fatigue (45%), headache (38%), shivering (27%), fever (21%), and gastrointestinal symptoms (17%)
- The data are insufficient to establish if there is vaccine-associated risk with SHINGRIX in pregnant women
- It is not known whether SHINGRIX is excreted in human milk. Data are not available to assess the effects of SHINGRIX on the breastfed infant or on milk production/excretion
- Vaccination with SHINGRIX may not result in protection of all vaccine recipients

Please see additional Important Safety Information on the first page and full [Prescribing Information](#) also available at SHINGRIXHCP.com.

CDC=Centers for Disease Control and Prevention; COVID-19=coronavirus disease 2019; Tdap=tetanus, diphtheria, and pertussis.

References: **1.** Harpaz R, et al. *MMWR Recomm Rep*. 2008;57(RR-5):1-30. **2.** Berlinberg EJ, et al. *J Clin Virol*. 2020;126:104306. **3.** Centers for Disease Control and Prevention. Reviewed July 19, 2024. Accessed August 19, 2024. <https://www.cdc.gov/shingles/hcp/vaccine-considerations/index.html> **4.** Prescribing Information for SHINGRIX.

Trademarks are property of their respective owners.

©2024 GSK or licensor.
PMUS-SGXLBN240006 August 2024
Produced in USA. 0002-0032-84



SHINGRIX
(ZOSTER VACCINE
RECOMBINANT, ADJUVANTED)

